Tambulin 是一种具有口服活性的黄酮醇类化合物,存在于 Zanthoxylum armatum 中,可抑制细胞增殖、诱导凋亡 (apoptosis) 并抑制活性氧 (ROS) 的产生,上调 cleaved caspase-3、cleaved caspase-9 和 Bax 并下调 Bcl-2 水平,刺激葡萄糖依赖性胰岛素分泌并诱导内皮非依赖性血管舒张,与琥珀酸脱氢酶 (SDH) 结合 (Ki = 11.02 μM) 并表现出显著的铁离子还原能力,还可增强氧化应激抵抗力,减少脂褐素沉积、脂质水平和 α-突触核蛋白 (α-synuclein) 水平,改善年龄同步化的 L1 雌雄同体秀丽隐杆线虫衰老及帕金森病模型中的运动行为和多巴胺水平,可用于帕金森病、肺鳞状细胞癌和糖尿病的研究。
产品编号: MS-D90605 CAS No.: 571-72-2 分子式: C18H16O7 分子量: 344.32
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Tambulin 是一种具有口服活性的黄酮醇类化合物,存在于 Zanthoxylum armatum 中,可抑制细胞增殖、诱导凋亡 (apoptosis) 并抑制活性氧 (ROS) 的产生,上调 cleaved caspase-3、cleaved caspase-9 和 Bax 并下调 Bcl-2 水平,刺激葡萄糖依赖性胰岛素分泌并诱导内皮非依赖性血管舒张,与琥珀酸脱氢酶 (SDH) 结合 (Ki = 11.02 μM) 并表现出显著的铁离子还原能力,还可增强氧化应激抵抗力,减少脂褐素沉积、脂质水平和 α-突触核蛋白 (α-synuclein) 水平,改善年龄同步化的 L1 雌雄同体秀丽隐杆线虫衰老及帕金森病模型中的运动行为和多巴胺水平,可用于帕金森病、肺鳞状细胞癌和糖尿病的研究。

生物实验数据

生物活性 Tambulin is an orally active flavonol compound found in Zanthoxylum armatum that inhibits cell proliferation, induces apoptosis and suppresses reactive oxygen species (ROS) production, upregulates cleaved caspase-3, cleaved caspase-9 and Bax while downregulating Bcl-2 levels, stimulates glucose-dependent insulin secretion and induces endothelium-independent vasodilation, binds to succinate dehydrogenase (SDH) (Ki = 11.02 μM) and exhibits significant ferric ion reducing ability, and also enhances oxidative stress resistance, reduces lipofuscin deposition, lipid levels and α-synuclein levels, and improves motor behavior and dopamine levels in age-synchronized L1 hermaphrodite Caenorhabditis elegans aging and Parkinson's disease models, making it useful for research on Parkinson's disease, lung squamous cell carcinoma and diabetes.
IC50 & Target

Caspase 3

 

Caspase-9

 

Bcl-2

 

Bax

 

体外研究
(In Vitro)

Tambulin (5-80 μg/mL; 12-48 h) 抑制 H226 和 H520 LSCC 细胞的增殖。
Tambulin (40 μg/mL) 诱导 H226 和 H520 LSCC 细胞凋亡,该效应被 HDAC1 过表达减弱。
Tambulin (40 μg/mL) 降低 H226 和 H520 LSCC 细胞中 HDAC1 和 Bcl-2 的表达,并增加 cleaved-caspase-3、9 和 Bax 的水平,这些效应被 HDAC1 过表达逆转。
Tambulin (100-400 µM; 60 min) 刺激分离的小鼠胰岛和 MIN6 细胞的葡萄糖依赖性胰岛素分泌。
Tambulin (30 min) 诱导猪冠状动脉环的内皮非依赖性血管舒张 (EC50 = 1.81 μM (去除内皮环),2.18 μM (完整内皮环))。
Tambulin (1 μM; 30 min) 增强由 Isoproterenol (MS-H12927)、Forskolin (MS-U03874) 和 Sodium nitroprusside (MS-S52919) 诱导的内皮细胞非依赖性舒张。
Tambulin (1-10 μM; 30 min) 以浓度依赖性方式抑制 KCl、5-HT、CaCl2 和 U46619 (MS-O09517) 诱导的收缩。
Tambulin (1 μM; 30 min) 不影响由 Bradykinin (MS-R97612)、A23187、钾通道激活剂 Levcromakalim (MS-G67361) 和 1-EBIO (MS-X50617) 以及 NO 非依赖性 sGC 激活剂 YC-1 (MS-A56268) 和 BAY 41-2272 (MS-F57770) 诱导的内皮松弛
Tambulin (10-50 μg/mL; 24 h) 抑制多种癌细胞和角质形成细胞系的增殖。
Tambulin 与琥珀酸脱氢酶 (SDH) 强力相互作用 (Ki = 11.02 μM)。
Tambulin (10-50 μg/mL) 显示显著的铁还原能力。

Cell Proliferation Assay

Cell Line: H226, H520 cells
Concentration: 5-80 μg/ml
Incubation Time: 12, 24, 48 h
Result: Inhibited H226 and H520 cell proliferation in a dose- and time-dependent manner with IC₅₀ values of 53.02 μg/ml (12 h), 40.86 μg/ml (24 h), 36.61 μg/ml (48 h) for H226 and 52.71 μg/ml (12 h), 39.95 μg/ml (24 h), 36.90 μg/ml (48 h) for H520.

Cell Proliferation Assay

Cell Line: MCF-7, WRL-68, COLO-205, MDA-MB-231, HaCaT
Concentration: 10, 20 and 50 μg/mL
Incubation Time: 24 h
Result: Exhibited antiproliferative activity against tested cell lines with IC₅₀ values of 39.43, 37.96, 45.84, 39.77 and 48.7 μg/mL.
体内研究
(In Vivo)

Tambulin (25-100 μM) 延长寿命,增强氧化应激抵抗力,降低 ROS 水平、脂褐素沉积、蛋白羰基含量、脂质水平、α-突触核蛋白水平和细胞凋亡,改善运动行为、咽泵频率和多巴胺水平,并上调年龄同步化的 L1 雌雄同体秀丽隐杆线虫衰老和帕金森病模型中的基因表达。
Tambulin (20-80 mg/kg; p.o.; daily; 28 days) 抑制雄性 Balb/c 裸鼠肺鳞状细胞癌 CDX 肿瘤生长。

Animal Model: age-synchronized L1 hermaphrodite Caenorhabditis elegans models of ageing and Parkinson's disease
Dosage: 25, 50, 100 μM
Administration: Incubation until death
Result: Increased mean lifespan of wild-type worms by 16.79% (23.336 ± 0.565 days vs. 19.981 ± 0.589 days control) at 50 μM.
Enhanced oxidative stress resistance (90% survival at 50 μM vs. 60% control).
Reduced intracellular ROS levels (40.9225 ± 1.99 RFU at 50 μM vs. control) and decreased lipofuscin deposits (117.817 ± 10.438 RFU vs. 166.448 ± 12.98 RFU control) and protein carbonyl content (57.377 ± 1.96% vs. control).
Upregulated mRNA expression of sod-1, sod-3, ctl-2, and daf-16 and increased lifespan of daf-16 mutant worms by 3.46% at 50 μM.
Reduced lipid levels in wild-type (90.10 ± 1.54 RFU vs. 106.8 ± 4.63 RFU control) and NL5901 worms (76.0 ± 1.95 RFU vs. 87.92 ± 1.68 RFU control).
Enhanced locomotary behavior (body bends: 7.66 ± 0.167 in N2, 7.875 ± 0.154 in NL5901 vs. 6.71 ± 0.18 and 6.56 ± 0.29 control; head thrashes: 166.5 ± 1.46 in N2, 168.1 ± 2.39 in NL5901 vs. 158.7 ± 2.02 and 153.8 ± 0.263 control).
Increased pharyngeal pumping (65.00 ± 0.75 in N2, 65.36 ± 0.67 in NL5901 vs. 60.45 ± 1.03 and 60.09 ± 0.73 control).
Decreased apoptosis (average score: 2.17 ± 0.025 in N2, 3.07 ± 0.075 in NL5901 vs. 2.87 ± 0.075 and 3.5 ± 0.05 control) and reduced α-synuclein levels (24.0289 ± 0.877 RFU vs. 29.81 ± 1.03 RFU control).
Augmented dopamine levels (9.04 ± 0.065 ng/ml in N2, 11.49 ± 0.04 ng/ml in NL5901 vs. 7.70 and 7.137 ng/ml control) and upregulated mRNA expression of lagr-1, pdr-1, lrk-1, ubc-12, and ymel-1 in NL5901 worms.
Animal Model: Balb/c nude mice (male, 4 to 6 weeks old, 18 to 22 g, CDX model with H226 or H520 cells)
Dosage: 20, 40, 80 mg/kg
Administration: p.o.; daily; 28 days
Result: Inhibited H226 and H520 CDX tumor growth in a dose-dependent manner with 80 mg/kg being the most effective.
Combined with Cisplatin (MS-E94993) to inhibit tumor growth more significantly than either agent alone.
Downregulated HDAC1 and Bcl-2 expression, and upregulated cleaved caspase-3 and Bax expression; these effects were reversed by HDAC1 overexpression.

化学信息

分子量 344.32
分子式 C18H16O7
CAS No. 571-72-2

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础